Weight-loss drugs are already dropping in price; could they go even lower?
The price of weight loss drugs is falling, making them more accessible to consumers, and the price could get driven even lower.
Highly sought-after drugs like Wegovy and Zepbound both retail at roughly $1,000 each and have been difficult for people without insurance to obtain.
Despite the price drops, the drugs remain costly. Novo Nordisk cut the price of Wegovy by 23 percent for cash payments from $650 to $499 for uninsured patients or people without coverage. The drug's list price of $1,349 has remained unchanged.
Meanwhile, Eli Lilly reduced Zepbound's starter dose to $349 and higher doses to $499 after launching a self-pay program called Lilly Direct. The new doses require patients to manually draw medication from a vial with a syringe.
In prior years, people would pay about $1,500 a month for the drugs, but in recent months have been able to obtain the doses for roughly $400 to $500, according to NBC News.
A May 2024 survey from the health policy group KFF found that half of U.S. adults say it's difficult to afford the medication.
Pressure from Congress and increased competition are some of the factors that led the drugmakers to reduce the cost. This has led to patients paying less out of pocket because they can afford the cheaper prices or their insurance now covers the drugs. More insurance plans have allowed for the drugs because they have been proven to treat heart disease risk and obstructive sleep apnea.
This month, a study published in the New England Journal of Medicine found Zepbound outperformed Wegovy in a head-to-head clinical trial.
Dr David Rind, a primary care physician and the chief medical officer for the Institute for Clinical and Economic Review, told NBC News: 'You're talking $6,000 a year, and that is still probably more than insurers are paying right now.'
He continued: 'If insurance is relying on the fact that not covering it will allow people to buy it out of pocket, as a primary care doctor, I have a lot of concerns about that...For all my complaining about the price, these are drugs that we should want to give to lots of people, but it's been really hard to see how we can afford them.'
But Rind said not to expect dramatic price drops in the foreseeable future. He said those cuts are likely to come when other weight-loss drugs being developed are approved, which could take several years.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Health Line
7 hours ago
- Health Line
GLP-1 Drugs Linked to Age-Related Macular Degeneration, Study Finds
GLP-1 drugs are associated with a higher risk of 'wet' age-related macular degeneration in people with type 2 diabetes, according to a new study. Researchers found that the risk substantially increased the longer people were prescribed a GLP-1 drug, particularly those containing semaglutide. GLP-1 medications like Ozempic and Wegovy have surged in popularity as weight loss treatments, but ophthalmologists say their potential risks to eye health are not well understood. GLP-1 drugs are linked to a significantly higher risk of developing neovascular or 'wet' age-related macular degeneration, according to new research. The study, conducted by researchers at the University of Toronto, found that people with type 2 diabetes who were prescribed GLP-1s were more than twice as likely to develop wet AMD as those who weren't. The study also found that the longer subjects were treated with these medications, the greater their risk of developing wet AMD. Neovascular age-related macular degeneration, commonly known as wet AMD, is the less common but more aggressive form of age-related macular degeneration, and a leading cause of irreversible vision loss among older adults in the United States. The findings, published on June 5 in JAMA Ophthalmology, suggest that doctors and patients should be aware of the potential risks, even though the chance of developing the condition remains relatively low. GLP-1 drugs, a class of blockbuster diabetes and obesity drugs sold under brand names like Ozempic and Wegovy, have surged in popularity in recent years. They offer a range of substantial benefits, including weight loss, improved blood sugar levels, and reduced cardiovascular disease risk. Despite these benefits, ophthalmologists say the impact of GLP-1 drugs on eye health is not well understood. Studies have identified an association between the medications and other eye conditions, including diabetic retinopathy and non-arteritic anterior ischemic optic neuropathy (NAION). While the findings don't establish a clear causal link between GLP-1 drugs and eye disease, experts say there's still reason for caution. 'The dose-response effect we observed — where longer GLP-1 receptor agonist exposure was associated with higher risk — strengthens the argument that this association may reflect a true biological effect rather than being due to confounding factors,' said study co-author Andrew Mihalache, MD(C), of the Temerty Faculty of Medicine at the University of Toronto, Canada. 'Seeing a graded relationship like this suggests that prolonged exposure could play a causal role in increasing risk. However, this needs to be confirmed in future studies,' he told Healthline. Long-term GLP-1 drug use may triple wet AMD risk Drawing on health records from Ontario, Canada, researchers at the University of Toronto analyzed nearly 140,000 adults with type 2 diabetes to investigate a possible link between GLP-1 use and wet AMD. The retrospective study tracked patient outcomes over a three-year period, using data collected between 2020 and 2023. Roughly one-third of participants — about 46,000 people — had been prescribed a GLP-1 drug for at least six months. The rest had not. In the vast majority of cases (97.5%), that drug was semaglutide, the active ingredient in Ozempic and Wegovy. The average participant was 66, and the cohort was almost evenly divided by sex, with females representing 46.6% of the group. On average, those who were prescribed a GLP-1 drug were more than twice as likely to be diagnosed with wet AMD. However, that number doesn't tell the full story. People who took GLP-1 drugs for longer experienced progressively greater risk. Those who had only taken their medication for 6–18 months actually had a slightly lower risk than those who didn't take the medication. However, at the 18–30 month mark, GLP-1 users' risk of developing wet AMD more than doubled compared to non-users. And those taking the drugs for 30 months or longer had more than triple the risk. 'This was definitely surprising, especially given the growing enthusiasm for GLP-1 receptor agonists for their cardiovascular and metabolic benefits. It really highlights the need for further investigation into their ocular safety profile,' first study author Reut Shor, MD, of the Department of Ophthalmology and Vision Sciences at the University of Toronto, Canada, told Healthline. Despite the increase in risk, the absolute risk of developing wet AMD was still low: 0.2% among those taking a GLP-1 and 0.1% among those who didn't. Do GLP-1 drugs harm eye health? While not definitive, the study raises further questions about the potential risks posed by GLP-1 drugs for eye health. Prior studies have also identified links between GLP-1s and other forms of eye disease in people with type 2 diabetes. In a major phase 3 semaglutide trial in 2016, researchers identified that type 2 diabetes patients taking semaglutide had a higher risk of complications of diabetic retinopathy compared to a placebo. Those findings were published in The New England Journal of Medicine. However, other studies have provided conflicting evidence. A retrospective 2024 study evaluated nearly 700 subjects with type 2 diabetes who were taking a GLP-1 drug and found no association between GLP-1s and worsening retinopathy. Also in 2024, researchers found that patients with type 2 diabetes who were prescribed semaglutide were at greater risk of NAION compared to those who weren't. NAION is a condition that causes sudden blindness, typically just in one eye, due to a lack of blood flow to the optic nerve. The mechanism for why GLP-1 drug use may lead to wet AMD is not well established, but a predominant theory is that lowering blood sugar rapidly leads to a lack of oxygen in the retina. 'When you make the retina more hypoxic, which is what the GLP-1s do, it basically pushes it further over the threshold, causing more abnormal blood vessels to grow,' said Linda Lam, MD, MBA, an ophthalmologist with Keck Medicine of USC, who wasn't involved in the research. Abnormal blood vessel growth in the eye is the hallmark of wet AMD. While GLP-1s offer many health benefits, eye disease risk must be considered in some populations, Lam told Healthline. 'In this particular group of patients who are older, who are diabetics, I really would caution against the extended use of GLP-1s,' she said. Lam reiterated the importance of annual eye exams for the general population, but in particular for those with diabetes, to identify and diagnose eye disease early on. People with type 2 diabetes, especially those taking a GLP-1 drug, should be aware of the signs and symptoms of vision loss and consult with their doctor immediately. These include:
Yahoo
7 hours ago
- Yahoo
How RFK Jr. is quickly changing U.S. health agencies
WASHINGTON — In just a few short months, Health and Human Services Secretary Robert F. Kennedy Jr. has begun to transform U.S. health policy: shrinking staff at health agencies, restructuring the focus of some regulators and researchers, changing Covid vaccine regulations and reshaping the mission of his department to focus more on alternative medicine. The directives are all part of the same issue set that drove a slice of health-conscious, left-leaning Americans to eventually vote for a Republican president whose favorite meal is from McDonald's, Trump and Kennedy catered to a type of voter who has grown distrustful of America's health care establishment — but possibly fomented a new type of distrust in federal health policy along the way. Bernadine Francis, a lifelong Democrat who backed Joe Biden for president in 2020 before supporting Donald Trump in 2024, told NBC News in an interview that she approves of Kennedy's efforts so far, despite his 'hands being tied' by entrenched forces in the administration and in Congress. 'From what I have seen so far with what RFK has been trying to do,' she said, 'I am really, really proud of what he's doing.' Francis is among the voters who left the Democratic Party and voted for Trump because 'nothing else mattered' apart from public health, which they — like Kennedy — felt was going in the wrong direction. Concerns about chemicals in food and toxins in the environment, long championed by Democrats, has become a galvanizing issue to a key portion of Trump's Republican Party, complete with an oversaturation of information that in some cases hasn't been proven. It's wrapped up, as well, in concerns about the Covid vaccine, which was accelerated under Trump, administered under Biden and weaponized by anti-vaccine activists like Kennedy amid lockdowns and firings in the wake of the devastating pandemic. 'We knew in order to get RFK in there so he can help with the situation that we have in the health industry, we knew we had to do this,' said Francis, a retired Washington, D.C., public school administrator, who said she left her 'beloved' career because she had refused the vaccine. 'It seemed to me, as soon as [Biden] became president, the vaccine was mandated, and that was when I lost all hope in the Democrats,' Francis told NBC News, referring to vaccination mandates put in place by the Biden administration for a large portion of the federal workforce during the height of the pandemic. There are not currently any federal Covid vaccine mandates. There have been 1,228,393 confirmed Covid deaths in the United States since the start of the pandemic, according to data from the Centers for Disease Control and Prevention. Dr. Marty Makary, Kennedy's hand-picked commissioner of the Food and Drug Administration and a John Hopkins scientist and researcher, told NBC News in an interview that he wants to transform the agency, which he said faced 'corruption' over influence from the pharmaceutical and food industries. 'I mean, you look at the food pyramid, it was not based on what's best for you, it was based on what companies wanted you to buy,' he said, referring to the 1992 and later iterations of official government nutritional guidance. He said there would be 'entirely new nutrition guidance' released later this year, as soon as this summer. He praised the FDA's mission of research and regulation, saying the agency is 'incredibly well-oiled, and we've got the trains running on time.' He also highlighted the 75-page 'Make America Healthy Again' commission report — which focused on ultraprocessed foods and toxins in the environment — as having set 'the agenda for research' at the FDA, HHS and agencies overseeing social safety net programs such as Medicare and food stamps moving forward. (The MAHA report initially cited some studies that didn't exist, a mistake that Kennedy adviser Calley Means said was a 'great disservice' to their mission.) 'I think there's a lot we're going to learn. For example, the microbiome, which gets attention in the MAHA report, needs to be on the map. We don't even talk about it in our medical circles,' Makary said. 'The microbiome, food is medicine, the immune response that happens when chemicals that don't appear in nature go down our GI tract.' Pressed on other areas of the administration, like the Environmental Protection Agency, making decisions that run counter to the pro-regulatory ideas presented in the MAHA report, Makary said he can 'only comment on the FDA' where they are 'committed to Secretary Kennedy's vision.' But Kennedy's public health agenda goes beyond looking at the food supply and chemicals. Recently, Kennedy said in a video posted on X last month that the Covid vaccine is no longer recommended for healthy children and pregnant women, a change in CDC guidance that skipped the normal public review period. Days later, after critics questioned the decision and raised concerns over a lack of public data behind the move, the administration updated its guidance again, urging parents to consult with their doctors instead. Pressed about the confusion and whether Americans are now trading one side of public distrust in the health system for another, Makary defended Kennedy, who has been criticized for spreading misinformation. 'My experience with Secretary Robert F. Kennedy is that he listens. He listens to myself, he listens to Jay Bhattacharya, listens to Dr. Mehmet Oz, he listens to a host of scientists that are giving him guidance,' Makary argued, referring to the director of the National Institutes of Health and the administrator for the Centers for Medicare & Medicaid Services, respectively. 'So he may have big questions, but the questions he's asking are the questions most Americans are asking.' Dr. Dawn Mussallem, a breast cancer oncologist and integrative medicine doctor — a physician who combines conventional treatments with research-based alternative therapies — has tried to help her patients wade through medical misinformation they encounter online and in their social circles. Mussallem has an incredible story of personal survival: While in medical school, she was diagnosed with Stage IV cancer and, after conventional therapies like chemo saved her life, was diagnosed with heart failure. After undergoing a heart transplant, Mussallem ran a 26-mile marathon just one year later. 'I learned a lot in medical school, but nothing compared to what I learned being a patient,' said Mussallem, who dedicates, on average, 90 minutes each in one-on-one sessions with her patients. 'This is not about any one political choice. But we know lifestyle matters.' For example, a new study from the American Society of Clinical Oncology that finds eating food that lowers inflammation in the body may help people with advanced colon cancer survive longer. Mussallem's mission, along with her colleagues, is to elevate the modern medicine that saved her life, as well as encouraging her patients to live healthy lifestyles, including regular exercise, minimally processed foods, less screen time, more social connection and better sleep. But politics do get in the way for millions of Americans who are inundated daily with social media influencers and 'nonmedical experts,' as Mussallem puts it, who stoke fear in her patients. 'Patients come in with all these questions, fears,' she said. 'I've heard this many times from patients, that their nervous system is affected by what they're seeing happening in government.' Mussallem acknowledges that 'a lot of individuals out there' have questioned traditional medicine. For her, it isn't one or the other — it's both. 'We have to trust the conventional medicine,' she said. 'With the conventional care that marches right alongside more of an integrative modality to look at the root causes of disease, as well as to help to optimize with lifestyle, is where we need to be.' This article was originally published on
Yahoo
8 hours ago
- Yahoo
Tesla stock sinks as Musk and Trump ridicule each other
One day after seeing their largest-ever one-day drop, Tesla shares recovered some losses Friday as the spat between CEO Elon Musk and President Donald Trump that exploded into public view Thursday took appeared to take a breather heading into the weekend. Shares in the electronic vehicle maker gained as much as 5% amid broader market gains following a report showing the U.S. added more jobs in May than forecast. Even with Friday's rally, Tesla shares are still down approximately 21% in 2025 — a decline that accelerated last week following Musk's departure from the Trump administration. Musk, the world's richest person and until recently Trump's cost-cutter-in-chief, said last week he was leaving as the head of his Department of Government Efficiency project to refocus on his businesses. Those companies — Tesla, the satellite and space-launch company SpaceX, the social media platform X and the brain tech startup Neuralink — have faced growing criticism as Musk oversaw deep cuts to the federal workforce. Tesla sales around the world have fallen sharply this year. Trump and Musk traded escalating insults Thursday afternoon, with the president threatening on his Truth Social platform to "terminate Elon's Governmental Subsidies and Contracts." Yet there was no sign of any follow through on the threat Friday. At the same time, a senior White House official told NBC News that Trump is 'not interested' in a call with Musk. Tesla stock closed more than 14% lower Thursday. The automaker is Musk's only publicly traded company — and one that the president tried to boost as recently as March, drawing sharp criticism on ethical grounds for turning the White House driveway into a car showroom just as the company's stock was plunging. The Trump-Musk rift has dented Tesla's stock anew after Musk slammed the GOP spending bill as "a disgusting abomination' in a post on X last week. "Bankrupting America is NOT ok!" he wrote in another post, part of an ongoing barrage of public ridicule. Musk began speaking out after an electric-vehicle tax credit that would help incentivize Tesla purchases was not included in the bill, which is estimated to add $2.4 trillion to the national debt over 10 years. Musk has lobbied congressional Republicans for that tax credit, NBC News reported Wednesday. "I was, like, disappointed to see the massive spending bill, frankly, which increases the budget deficit, doesn't decrease it, and undermines the work that the DOGE team is doing," Musk told "CBS Sunday Morning" over the weekend. As Trump spoke about the former DOGE chief in the Oval Office on Thursday alongside German Chancellor Friedrich Merz, Musk began firing off dozens of posts on X. "Whatever," he wrote. "Keep the EV/solar incentive cuts in the bill, even though no oil & gas subsidies are touched (very unfair!!), but ditch the MOUNTAIN of DISGUSTING PORK in the bill. In the entire history of civilization, there has never been legislation that both big and beautiful. Everyone knows this!" Trump pushed back further on Musk's criticism. 'Elon knew the inner workings of this bill better than almost anybody sitting here, better than you people. He knew everything about it. He had no problem with it,' he said during the meeting with Merz. 'All of a sudden he had a problem, and he only developed the problem when he found out that we're going to have to cut the EV mandate because that's billions and billions of dollars, and it really is unfair.' As Trump continued speaking, Musk posted another comment: "False, this bill was never shown to me even once and was passed in the dead of night so fast that almost no one in Congress could even read it!" Tech analyst Dan Ives said the EV tax credit isn't the main factor behind Tesla's stock slide. 'The reason Tesla stock's off the way it is — and I think overdone — is because of the view that this means that Trump is not going to play nice when it comes to regulatory' issues, he told CNBC on Thursday. The feud between the two men is 'not what you want to see as a Tesla shareholder,' Ives added. "Where is this guy today??" Musk added Thursday in yet another post, resharing a compilation of Trump's past tweets including one in which Trump called the federal debt "a national security risk of the highest order." "Without me, Trump would have lost the election, Dems would control the House and the Republicans would be 51-49 in the Senate," Musk added on social media. "Such ingratitude." Musk is the richest person on the planet, according to the Bloomberg Billionaires index. His net worth of $368 billion is $125 billion more than that of Meta CEO Mark Zuckerberg, who is ranked second. Musk spent $250 million supporting Trump's most recent campaign. The president quipped from the White House that he thinks Musk "misses the place." "I think he got out there and all of a sudden he wasn't in this beautiful Oval Office," Trump said. "He's got nice offices too, but there's something about this one." The president's own publicly traded company, Trump Media & Technology Group, has also suffered in the market. Shares of the Truth Social parent company fell more than 8% Thursday and are down over 41% so far this year. This article was originally published on Sign in to access your portfolio
